Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology

The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on in...

Descripción completa

Detalles Bibliográficos
Autores principales: Fusco, Vittorio, Campisi, Giuseppina, de Boissieu, Paul, Monaco, Federico, Baraldi, Anna, Numico, Gianmauro, Bedogni, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162673/
https://www.ncbi.nlm.nih.gov/pubmed/30200393
http://dx.doi.org/10.3390/dj6030042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162673/
https://www.ncbi.nlm.nih.gov/pubmed/30200393
http://dx.doi.org/10.3390/dj6030042

Ejemplares similares